Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT04526899
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
- NCT04526899 ↗
- Completed
- BioNTech SE
- Focused
We haven't built an HCP commentary report on NCT04526899 (BNT111 and cemiplimab in Melanoma Stage III) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04526899 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Melanoma Stage III; Melanoma Stage IV; Unresectable Melanoma
- Interventions
- BNT111; Cemiplimab
- Arms
- BNT111 + cemiplimab · Experimental
- BNT111 monotherapy · Experimental
- Cemiplimab monotherapy · Experimental
- Enrollment
- 184
- Primary outcomes
- Arm 1: Objective Response Rate (ORR)
- Sponsor
- BioNTech SE with Regeneron Pharmaceuticals
- Start
- May 19, 2021
- Primary completion
- Jan 25, 2024
- Results posted
- Yes
- Registry record
- NCT04526899 · updated Jan 8, 2026